Liver cancer screening is a standardized diagnostic surveillance protocol designed to detect primary liver tumors—primarily hepatocellular carcinoma (HCC)—in individuals with elevated baseline risk. Recommended by international bodies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), screening typically involves transabdominal ultrasound paired with serum alpha-fetoprotein (AFP) testing every six months. The primary objective is identifying malignant lesions when they are smaller than two to three centimeters, enabling curative interventions like surgical removal, radiofrequency ablation, or liver transplantation.

Liver cancer screening consists of two synchronized diagnostic components performed during a single outpatient visit: an abdominal ultrasound imaging scan and a venous blood draw. The ultrasound technician places water-based acoustic gel on the upper abdomen and glides a transducer over the right upper quadrant to visualize the liver parenchyma, hepatic veins, and portal vein architecture. Concurrently, a laboratory technician draws a blood sample to measure serum alpha-fetoprotein (AFP) concentrations. If ultrasound imaging identifies a solid liver nodule measuring one centimeter or greater, multiphase contrast-enhanced CT or MRI is scheduled to evaluate characteristic tumor blood flow patterns.

Regular surveillance offers critical clinical benefits for patients with chronic liver conditions. According to AASLD surveillance guidelines, semi-annual screening increases the detection rate of early-stage, operable liver lesions from under 30% to over 60–70%. Identifying lesions early expands access to curative options—including liver transplantation and surgical removal—and significantly enhances overall five-year survival metrics compared to late-stage symptom-led diagnosis.

Because screening procedures consist solely of external abdominal ultrasound scans and standard peripheral blood draws, there is no physical recovery period required. Patients immediately resume normal work routines, physical exercise, normal diet, and driving after completing their appointments. Ongoing management involves repeating the screening protocol every six months as long as results remain negative.

Liver cancer screening is applied for surveillance in individuals at high risk for hepatocellular carcinoma (HCC) and early dysplastic nodules. Specific target populations include adults with liver cirrhosis from any cause, chronic hepatitis B virus infection, chronic hepatitis C virus infection with advanced hepatic fibrosis, non-alcoholic fatty liver disease with advanced fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), alcohol-related liver disease, and hereditary liver conditions such as alpha-1 antitrypsin deficiency or hemochromatosis.

Patients preparing for upper abdominal ultrasound screening must fast from solid food and beverages other than plain water for four to six hours prior to the procedure. Fasting minimizes upper gastrointestinal gas interference and ensures proper gallbladder distension for clearer tissue visualization. Routine prescription medications can be taken with small sips of water unless directed otherwise by the physician. No dietary or fasting preparations are required for the serum alpha-fetoprotein blood draw. Wearing comfortable, loose-fitting two-piece clothing is recommended to allow easy access to the abdominal region.

Transabdominal ultrasound and standard venous blood draws carry minimal physiological risk. Ultrasound relies on sound waves and involves zero exposure to ionizing radiation. Venipuncture carries minor localized risks, such as temporary bruising, mild discomfort at the needle puncture site, lightheadedness, or rarely, localized superficial infection. Diagnostic follow-up imaging, if required, may involve low-dose ionizing radiation (CT) or intravenous contrast agents, which present small risks of allergic reaction or temporary kidney strain in susceptible individuals.

The screening process begins with a medical evaluation to confirm eligibility based on clinical risk factors, such as cirrhosis or chronic viral hepatitis. Patients undergo outpatient surveillance every six months, consisting of an upper abdominal ultrasound and a routine blood draw. If testing detects a suspicious liver lesion or elevated protein markers, diagnostic cross-sectional imaging—such as multiphase computed tomography (CT) or magnetic resonance imaging (MRI)—is performed to establish a definitive diagnosis. Confirmed early-stage cases are referred to a multidisciplinary liver tumor panel to establish an individualized curative treatment plan.